# ARHGAP4

## Overview
ARHGAP4 is a gene that encodes the Rho GTPase activating protein 4, a member of the RhoGAP family, which plays a pivotal role in the regulation of cytoskeletal dynamics. This protein is characterized by its modular structure, including an N-terminal FCH domain, a central GAP domain, and a C-terminal SH3 domain, which facilitate its interactions with actin-binding proteins and other components involved in cytoskeletal rearrangement (Vogt2007ARHGAP4). Predominantly expressed in the nervous system and hematopoietic cells, Rho GTPase activating protein 4 is crucial for modulating cell motility and axon outgrowth by inactivating small GTPases such as RhoA, Rac1, and Cdc42 (Okada2011SH3; Aspenström2018BAR). The protein's regulatory functions are significant in various physiological processes and have implications in pathological conditions, including cancer, where its expression levels can influence disease progression and prognosis (Shen2019ARHGAP4; Xiao2024Rho).

## Structure
ARHGAP4 is a Rho GTPase-activating protein characterized by several distinct domains that contribute to its function in regulating cytoskeletal dynamics. The protein contains an N-terminal FCH (Fps/Fes/CIP4 homology) domain, a central GAP (GTPase-activating protein) domain, and a C-terminal SH3 (Src homology 3) domain (Vogt2007ARHGAP4). The FCH domain is crucial for localizing ARHGAP4 to the leading edges of migrating cells and axon growth cones, while the GAP domain is essential for its inhibitory function on cell and axon motility (Vogt2007ARHGAP4). The SH3 domain facilitates interactions with proline-rich domains of other proteins, including actin-binding proteins (Vogt2007ARHGAP4).

ARHGAP4 is structurally similar to other proteins in the RhoGAP family, such as CIP4, which also possess FCH and SH3 domains (Vogt2007ARHGAP4). The protein is predominantly expressed in the nervous system and hematopoietic cells, where it plays a role in actin polymerization regulation (Okada2011SH3; Aspenström2018BAR). While specific details on the primary, secondary, tertiary, or quaternary structures are not provided, the presence of these domains suggests a modular architecture typical of RhoGAP proteins. The protein's activity and localization are influenced by its interactions with actin filaments rather than microtubules (Vogt2007ARHGAP4).

## Function
ARHGAP4 encodes a Rho GTPase-activating protein that plays a crucial role in regulating cytoskeletal dynamics, particularly in cell motility and axon outgrowth. The protein functions by enhancing the hydrolysis of GTP to GDP in small GTPases such as RhoA, Rac1, and Cdc42, effectively switching them to their inactive state. This inactivation inhibits downstream signaling pathways that regulate actin filament dynamics, which is essential for controlling the assembly and disassembly of actin filaments at the leading edge of motile cells (Vogt2007ARHGAP4).

ARHGAP4 is localized to the leading edges of migrating cells and axon growth cones, where it interacts with actin filaments. Its activity is linked to the inhibition of Rac1 and Cdc42, which are associated with enhancing motility (Vogt2007ARHGAP4). The protein's function is also connected to a complex involving Hem-1, which organizes the leading edge of motile cells. During embryonic development, ARHGAP4 is widely distributed in the central nervous system, suggesting a central role in regulating cell and axon motility, which could be significant for CNS repair and recovery from injury or neurodegenerative diseases (Vogt2007ARHGAP4).

## Clinical Significance
ARHGAP4 has been implicated in various cancers, with its expression levels and interactions playing significant roles in disease progression and prognosis. In pancreatic cancer, higher expression of ARHGAP4 is associated with a favorable prognosis, as it inhibits metastasis through the HDAC2/β-catenin signaling pathway. Overexpression of ARHGAP4 reduces cell migration and invasion, suggesting its potential as a therapeutic target (Shen2019ARHGAP4).

In contrast, ARHGAP4 is upregulated in kidney renal clear cell carcinoma (KIRC) and is linked to poor prognosis and immune infiltration. High ARHGAP4 expression correlates with advanced cancer stages and worse survival outcomes, indicating its role in tumor progression and potential as a biomarker for diagnosis and prognosis (Xiao2024Rho).

In scirrhous-type gastric cancer, ARHGAP4 is overexpressed and associated with aggressive disease forms and poor prognosis. It is considered a candidate oncogene and a potential target for treatment (SERA2022Candidate).

In colorectal cancer, high ARHGAP4 expression is linked to poor prognosis and is associated with immune cell infiltration. It is involved in critical signaling pathways, including PI3K-AKT-mTOR and TGF-beta, and is considered a potential therapeutic target (Fu2022Analysis).

## Interactions
ARHGAP4 interacts with several proteins involved in actin polymerization and cytoskeletal dynamics. It binds to actin assembly activators WASF2 and DIAPH1, forming complexes that negatively regulate actin polymerization. This interaction is facilitated by the SH3 domain of ARHGAP4, which also associates with members of the WASF2 complex, including CYFIP1, NCKAP1, ABI1, ACTR2, and ARPC2 (Okada2011SH3). The SH3 domain of ARHGAP4 is crucial for its interaction with proline-rich domains of various proteins, including actin-binding proteins, suggesting its role in actin regulation (Vogt2007ARHGAP4).

ARHGAP4 also interacts with the scaffolding protein Hem-1, which is part of a complex targeted to the leading edge of polarized neutrophils. This interaction is part of the Rac/actin/PIP3 feedback loop, where ARHGAP4's GAP activity is localized to terminate Rac-mediated actin polymerization (Vogt2007ARHGAP4). Additionally, ARHGAP4 has been shown to interact with Rho family GTPases, including RhoA, Rac1, and Cdc42, modulating their activity and influencing cell motility and axon outgrowth (Vogt2007ARHGAP4; Aspenström2018BAR). These interactions highlight ARHGAP4's role in regulating cytoskeletal dynamics and cellular signaling pathways.


## References


[1. (Fu2022Analysis) Ming-sheng Fu, Shu-xian Pan, Xun-quan Cai, Yuan-xin Hu, Wei-jie Zhang, and Qin-cong Pan. Analysis of arhgap4 expression with colorectal cancer clinical characteristics and prognosis. Frontiers in Oncology, June 2022. URL: http://dx.doi.org/10.3389/fonc.2022.899837, doi:10.3389/fonc.2022.899837. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.899837)

[2. (Okada2011SH3) Hirokazu Okada, Akiyoshi Uezu, Frank M. Mason, Erik J. Soderblom, M. Arthur Moseley, and Scott H. Soderling. Sh3 domain–based phototrapping in living cells reveals rho family gap signaling complexes. Science Signaling, November 2011. URL: http://dx.doi.org/10.1126/scisignal.2002189, doi:10.1126/scisignal.2002189. This article has 36 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2002189)

[3. (Vogt2007ARHGAP4) D.L. Vogt, C.D. Gray, W.S. Young, S.A. Orellana, and A.T. Malouf. Arhgap4 is a novel rhogap that mediates inhibition of cell motility and axon outgrowth. Molecular and Cellular Neuroscience, 36(3):332–342, November 2007. URL: http://dx.doi.org/10.1016/j.mcn.2007.07.004, doi:10.1016/j.mcn.2007.07.004. This article has 50 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mcn.2007.07.004)

[4. (SERA2022Candidate) TOMOHIRO SERA, TAKASHI SAKUMA, KOJI MARUO, GEN TSUJIO, YURIE YAMAMOTO, ATSUSHI SUGIMOTO, SYUHEI KUSHIYAMA, SHINGO TOGANO, KENJI KURODA, HIROAKI KASASHIMA, MASAICHI OHIRA, and KIYOSHI MAEDA. Candidate oncogenes,arhgap4, nos3, andor51b5, for the development of scirrhous-type gastric cancer. Anticancer Research, 42(11):5195–5203, October 2022. URL: http://dx.doi.org/10.21873/anticanres.16026, doi:10.21873/anticanres.16026. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.21873/anticanres.16026)

[5. (Shen2019ARHGAP4) Yehua Shen, Litao Xu, Zhouyu Ning, Luming Liu, Junhua Lin, Hao Chen, and Zhiqiang Meng. Arhgap4 regulates the cell migration and invasion of pancreatic cancer by the hdac2/β-catenin signaling pathway. Carcinogenesis, 40(11):1405–1414, April 2019. URL: http://dx.doi.org/10.1093/carcin/bgz067, doi:10.1093/carcin/bgz067. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/carcin/bgz067)

[6. (Xiao2024Rho) Xuesong Xiao, Xiaofei Lv, Tianyu Lin, Jianqiao Li, Rui Wang, Shaoping Tian, Xinyu Liu, Shiming Liu, Huamao Jiang, Dan Yue, and Yong Wang. Rho gtpase-activating protein 4 is upregulated in kidney renal clear cell carcinoma and associated with poor prognosis and immune infiltration. Cancer Biomarkers, 40(2):205–223, July 2024. URL: http://dx.doi.org/10.3233/cbm-230388, doi:10.3233/cbm-230388. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3233/cbm-230388)

[7. (Aspenström2018BAR) Pontus Aspenström. BAR Domain Proteins Regulate Rho GTPase Signaling, pages 33–53. Springer International Publishing, 2018. URL: http://dx.doi.org/10.1007/5584_2018_259, doi:10.1007/5584_2018_259. This article has 7 citations.](https://doi.org/10.1007/5584_2018_259)